33,331 Results

UEG Week 2018

Anti-integrins in IBD

UEG Week 2018

A packed UEG Week looking into the world of gastroenterology saw several key talks given on ulcerative colitis and Crohn’s disease with a focus on involving patients in treatment decisions, how therapies are evolving and how best to optimise outcomes. You can watch videos from the Takeda-sponsored satellite symposia now including talks from Dr Peter Irving and Professor Geert D’Haens.

Five-year study shows SRT-100 benefits patients with non-melanoma skin cancer/- Sensus Healthcare

 Added 12 hours ago

Sensus Healthcare announced topline results from a five-year retrospective study of non-melanoma skin cancer (NMSC) patients treated with Superficial Radiation...

FDA approves TransPyloric Shuttle device for obesity.- BAROnova

 Added 12 hours ago

BAROnova announced that the FDA has approved the TransPyloric Shuttle (TPS) Device, a non-surgical weight loss solution for adult individuals...

FDA expands approval for KardiaMobile to include bradycardia and tachycardia detection.- AliveCor

 Added 12 hours ago

AliveCor announced two additional FDA 510(k)-cleared indications, making KardiaMobile the only consumer ECG device in the world with FDA-clearance to...

Safety and Tolerability of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria (PKU)

This study will evaluate SYNB1618 (investigational product) in healthy volunteers (HV) and subjects diagnosed with phenylketonuria (PKU) for the possible treatment of PKU. Phenylketonuria (PKU) is a rare inherited metabolic...

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD2)

This is the first prospective, multi-center, double-blinded, randomized controlled study of a microbiota suspension derived from intestinal microbes. Patients who have had at least two recurrences of C. difficile infection (CDI) after...

ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection (ECOSPORIII)

The purpose of this study is to demonstrate the superiority of SER-109 vs placebo to reduce recurrence of CDI in adults up to 8 weeks after initiation of treatment.

Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.

Objectives: To investigate the impact of previous biologic exposure on the efficacy and safety of brodalumab and ustekinumab in patients with moderate‐to‐severe plaque psoriasis.

Drug survival of biologic treatments in psoriasis: a systematic review.

Drug survival measures the length of time until discontinuation of a drug. The length of time a patient remains on a biologic drug is impacted by several factors such as tolerability, side effects, safety profile and effectiveness.

WILLIAM J. SANDBORN, MD

Anti-integrins in IBD

WILLIAM J. SANDBORN, MD

Load more